甲硫咪唑联合比索洛尔对甲亢患者的治疗效果及对血清OCNβ-CTx的影响分析

Therapeutic Effect of Methimazole combined with Bisoprolol on Hyperthyroidism and its Influence on Serum OCN and beta-CTx

目的:分析甲硫咪唑联合比索洛尔对甲亢患者的治疗效果及对血清骨钙素(OCN)、Ⅰ型胶原羧基端肽β特殊序列(β-CTx)的影响。方法:选择2015年2月至2017年2月我院接诊的85例甲亢患者作为本研究对象,通过简单随机数表法分为观察组(n=50)和对照组(n=50),对照组给予甲硫咪唑联合普萘洛尔治疗,观察组给予甲硫咪唑联合比索洛尔治疗,均连续治疗14d。比较两组临床疗效、甲状腺激素功能、血清OCN、β-CTx的变化和不良反应。结果:治疗后,观察组临床疗效总有效率为明显高于对照组(P <0.05);治疗后,两组促甲状腺激素(TSH)较治疗前均显著升高,游离甲状腺素(FT4)、游离三碘甲状腺原氨酸(FT3)显著降低(P<0.05),观察组TSH明显高于对照组,FT4、FT3明显比对照组低](P<0.05);治疗后,两组血清OCN、β-CTx比较较治疗前均显著降低(P<0.05),观察组血清OCN、β-CTx明显低于对照组(P<0.05);两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论:在甲亢患者中使用甲硫咪唑联合比索洛尔效果显著,可明显改善甲状腺功能,降低血清OCN、β-CTx的表达,安全性高,值得应用推广。

Objective: To analyze the therapeutic effect of methylthimidazole combined with bisoprolol on hyperthyroidism and its effect on serum osteocalcin (OCN) and specific sequence of collagen type I carboxyterminal peptide beta (beta-CTx). Methods: 85 patients with hyperthyroidism admitted to our hospital from February 2015 to February 2017 were selected as the subjects of this study. They were divided into observation group (n=50) and control group (n=50) by simple random number table method. The control group was treated with methimazole combined with propranolol, while the observation group was treated with methimazole combined with bisoprolol for 14 consecutive days. The clinical efficacy, thyroid hormone function, serum OCN, beta-CTx changes and adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of the observation group was significantly higher than that of the control group (P<0.05);After treatment, the thyroid stimulating hormone (TSH) of two groups were significantly higher than before treatment. TSH in the observation group was significantly higher than that in the control group, FT4 and FT3 were significantly lower than those in the control group (P<0.05). After treatment, the levels of serum OCN and beta-CTx in the two groups were significantly lower than those before treatment (P<0.05). The levels of serum OCN and beta-CTx in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: After treatment, the levels of serum OCN and beta-CTx in the two groups were significantly lower than those before treatment (P<0.05). The levels of serum OCN and beta-CTx in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).